Patents by Inventor Michael J. Kuhar

Michael J. Kuhar has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20080153870
    Abstract: A class of binding ligands for cocaine receptors and other receptors in the brain. Specifically, a novel family of compounds shows high binding specificity and activity, and, in a radiolabeled form, can be used to bind to these receptors, for biochemical assays and imaging techniques. Such imaging is useful for determining effective doses of new drug candidates in human populations. In addition, the high specificity, slow onset and long duration of the action of these compounds at the receptors makes them particularly well suited for therapeutic uses, for example as substitute medication for psychostimulant abuse. Some of these compounds may be useful in treating Parkinson's Disease or depression, by virtue of their inhibitory properties at monoamine transporters.
    Type: Application
    Filed: September 28, 2007
    Publication date: June 26, 2008
    Applicant: Research Triangle Institute
    Inventors: Michael J. KUHAR, Frank I. CARROLL, John W. BOJA, Anita H. LEWIN, Philip ABRAHAM
  • Patent number: 7291737
    Abstract: A class of binding ligands for cocaine receptors and other receptors in the brain. Specifically, a novel family of compounds shows high binding specificity and activity, and, in a radiolabeled form, can be used to bind to these receptors, for biochemical assays and imaging techniques. Such imaging is useful for determining effective doses of new drug candidates in human populations. In addition, the high specificity, slow onset and long duration of the action of these compounds at the receptors makes them particularly well suited for therapeutic uses, for example as substitute medication for psychostimulant abuse. Some of these compounds may be useful in treating Parkinson's Disease or depression, by virtue of their inhibitory properties at monoamine transporters.
    Type: Grant
    Filed: November 12, 2004
    Date of Patent: November 6, 2007
    Assignee: Research Triangle Institute
    Inventors: Michael J. Kuhar, Frank I. Carroll, John W. Boja, Anita H. Lewin, Philip Abraham
  • Patent number: 7189737
    Abstract: A class of binding ligands for cocaine receptors and other receptors in the brain. Specifically, a novel family of compounds shows high binding specificity and activity, and, in a radiolabeled form, can be used to bind to these receptors, for biochemical assays and imaging techniques. Such imaging is useful for determining effective doses of new drug candidates in human populations. In addition, the high specificity, slow onset and long duration of the action of these compounds at the receptors makes them particularly well suited for therapeutic uses, for example as substitute medication for psychostimulant abuse. Some of these compounds may be useful in treating Parkinson's Disease or depression, by virtue of their inhibitory properties at monoamine transporters.
    Type: Grant
    Filed: October 25, 2002
    Date of Patent: March 13, 2007
    Assignee: Research Triangle Institute
    Inventors: Michael J. Kuhar, Frank I. Carroll, John W. Boja, Anita H. Lewin, Philip Abraham
  • Patent number: 7011813
    Abstract: Tropane derivatives having a high binding affinity and selectivity for dopamine transporters bear, on the tropane backbone either a carboxylic ester or isoxazole moiety, as well as a substituted phenyl moiety. The compounds have utility both as pharmaceutical and as imaging agents, when one or more atoms are radioactive.
    Type: Grant
    Filed: May 28, 2002
    Date of Patent: March 14, 2006
    Assignee: Research Triangle Institute
    Inventors: Michael J. Kuhar, Frank Ivy Carroll, John W. Boja, Anita H. Lewin, Philip Abraham
  • Patent number: 6706880
    Abstract: The invention relates to novel compounds which show high affinity for cocaine receptors in the brain, particularly dopamine and serotonin transporter sites. The compounds may be used as imaging or pharmaceutical agents, in the diagnosis and treatment of drug addiction, depression, anorexia and neurodegenerative diseases or in determining the doses of therapeutic agents that occupy significant numbers of receptors.
    Type: Grant
    Filed: September 20, 2001
    Date of Patent: March 16, 2004
    Assignee: Research Triangle Institute
    Inventors: Frank I. Carroll, Michael J. Kuhar, John W. Boja, Anita H. Lewin, Philip Abraham
  • Publication number: 20030203934
    Abstract: A class of binding ligands for cocaine receptors and other receptors in the brain. Specifically, a novel family of compounds shows high binding specificity and activity, and, in a radiolabeled form, can be used to bind to these receptors, for biochemical assays and imaging techniques. Such imaging is useful for determining effective doses of new drug candidates in human populations. In addition, the high specificity, slow onset and long duration of the action of these compounds at the receptors makes them particularly well suited for therapeutic uses, for example as substitute medication for psychostimulant abuse. Some of these compounds may be useful in treating Parkinson's Disease or depression, by virtue of their inhibitory properties at monoamine transporters.
    Type: Application
    Filed: October 25, 2002
    Publication date: October 30, 2003
    Applicant: Research Triangle Institute
    Inventors: Michael J. Kuhar, Frank I. Carroll, John W. Boja, Anita H. Lewin, Philip Abraham
  • Patent number: 6531483
    Abstract: The invention relates to novel compounds which show high affinity for cocaine receptors in the brain, particularly dopamine and serotonin transporter sites. The compounds may be used as imaging or pharmaceutical agents, in the diagnosis and treatment of drug addiction, depression, anorexia and neurodegenerative diseases.
    Type: Grant
    Filed: September 4, 1996
    Date of Patent: March 11, 2003
    Assignee: Research Triangle Institute
    Inventors: Michael J. Kuhar, Frank I. Carroll, John W. Boja, Anita H. Lewin, Philip Abraham
  • Publication number: 20030023090
    Abstract: The invention relates to novel compounds which show high affinity for cocaine receptors in the brain, particularly dopamine and serotonin transporter sites. The compounds may be used as imaging or pharmaceutical agents, in the diagnosis and treatment of drug addiction, depression, anorexia and neurodegenerative diseases.
    Type: Application
    Filed: September 20, 2001
    Publication date: January 30, 2003
    Applicant: RESEARCH TRIANGLE INSTITUTE
    Inventors: Frank I. Carroll, Michael J. Kuhar, John W. Boja, Anita H. Lewin, Philip Abraham
  • Publication number: 20020188003
    Abstract: Tropane derivatives having a high binding affinity and selectivity for dopamine transporters bear, on the tropane backbone either a carboxylic ester or isoxazole moiety, as well as a substituted phenyl moiety. The compounds have utility both as pharmaceutical and as imaging agents, when one or more atoms are radioactive.
    Type: Application
    Filed: May 28, 2002
    Publication date: December 12, 2002
    Applicant: Research Triangle Institute
    Inventors: Michael J. Kuhar, Frank Ivy Carroll, John W. Boja, Anita H. Lewin, Philip Abraham
  • Patent number: 6358492
    Abstract: The 3&agr; isomer of RTI-55, RTI-352, is an effective in vivo binding ligand that reflects greater selectivity for the dopamine transporter than is observed with RTI-55. In addition, there is also a more rapid achievement of apparent equilibrium in the striatal-to-cerebellar ratio (compared to RTI-55) as the ratio peaks at about 30 min and is maintained for about 20 min thereafter. Such apparent equilibrium is useful in developing an approach to measuring the number of dopamine transporters present in tissues. Moreover, these results indicate that the utilization of 3&agr; isomers of a variety of 3&bgr;-(substituted phenyl)tropanes will result in greater selectivity for dopamine transporters and a more rapid of achievement of apparent equilibrium.
    Type: Grant
    Filed: October 7, 1997
    Date of Patent: March 19, 2002
    Assignee: Research Triangle Institute
    Inventors: Michael J. Kuhar, Frank I. Carroll, John W. Boja, Anita H. Lewin, Philip Abraham
  • Patent number: 6329520
    Abstract: The invention relates to novel compounds which show high affinity for cocaine receptors in the brain, particularly dopamine and serotonin transporter sites. The compounds may be used as imaging or pharmaceutical agents, in the diagnosis and treatment of drug addiction, depression, anorexia and neurodegenerative diseases or in determining the doses of therapeutic agents that occupy significant numbers of receptors.
    Type: Grant
    Filed: May 22, 1998
    Date of Patent: December 11, 2001
    Assignee: Research Triangle Institute
    Inventors: Frank I. Carroll, Michael J. Kuhar, John W. Boja, Anita H. Lewin, Philip Abraham
  • Patent number: 5935953
    Abstract: The invention relates to a method of controlling an invertebrate pest, comprising contacting the pest with a pest-controlling amount of an agent having substantial inhibitory activity toward a phenylethanolamine reuptake transporter as determined by radioactive octopamine reuptake inhibition assay is disclosed. Compositions comprising compounds capable of inhibiting the octopamine reuptake transporter include cocaine analogs. A process for inhibiting the feeding of an invertebrate pest comprising contacting said pest with a pest-controlling amount of an agent having substantial inhibitory activity toward a phenylethanolamine reuptake transporter as determined by radioactive octopamine reuptake inhibition assay, with the proviso that said agent is not cocaine. A process for delaying the maturation of a juvenile invertebrate by contacting it with an inhibitory amount of a phenylethanolamine reuptake transporter blocker is also disclosed.
    Type: Grant
    Filed: March 25, 1997
    Date of Patent: August 10, 1999
    Assignee: Research Triangle Institute
    Inventors: Michael J. Kuhar, Frank I. Carroll, John W. Boja, Anita H. Lewin, Philip Abraham
  • Patent number: 5496953
    Abstract: Novel compounds show high affinity for specific cocaine receptors in the brain, particularly dopamine transporter sites, and have the formula ##STR1## Wherein Y=CONRR.sub.2, R.sub.1 =hydrogen, C.sub.1-5 alkyl,X=H, C.sub.1-6 alkyl, C.sub.3-8 cycloalkyl, C.sub.1-4 alkoxy, C.sub.1-6 alkynyl, halogen, amino, acylamido,R and R.sup.2 may be saturated or unsaturated substituents of 1-6 carbon atoms, aromatic, or combine to form pyrrolidinyl, morpholinyl or piperidinyl moieties, andZ=H, I, Br, Cl, F, CN, CF.sub.3 NO.sub.2, N.sub.3, OR.sub.1, CO.sub.2 NH.sub.2, CO.sub.2 R.sub.1, C.sub.1-6 alkyl, NR.sub.4 R.sub.5, NHCOF.sub.5, NHCO.sub.2 R.sub.6,wherein R.sub.4 -R.sub.6 are each C.sub.1-6 alkyl.
    Type: Grant
    Filed: December 10, 1993
    Date of Patent: March 5, 1996
    Assignee: Research Triangle Institute
    Inventors: Michael J. Kuhar, Frank I. Carroll, Joh W. Boja, Anita H. Lewin, Philip Abraham
  • Patent number: 5413779
    Abstract: 3.beta.-[4-iodophenyl]-tropan-2.beta.-carboxylic acid methyl ester tartrate is a high affinity binding ligand for cocaine receptors in mammalian brains. It and its congeners may be employed for imaging and other brain scanning techniques that allow the determination of the presence of cocaine receptors, such as dopamine and serotonin transporters and the like.
    Type: Grant
    Filed: March 23, 1993
    Date of Patent: May 9, 1995
    Assignees: Research Triangle Institute, The United States of America represented by the Secretary of Health and Human Services
    Inventors: Michael J. Kuhar, Frank I. Carroll, John W. Boja, Anita H. Lewin, Philip Abraham
  • Patent number: 5380848
    Abstract: Novel compounds show high affinity for specific cocaine receptors in the brain, particularly dopamine transporter sites, and have the formula ##STR1## Wherein Y=CH.sub.2 R.sub.3, CO.sub.2 R.sub.2 or ##STR2## R.sub.1 =hydrogen, C.sub.1-5 alkyl, R.sub.2 =hydrogen, C.sub.1-6 alkyl, C.sub.3-8 cycloalkyl, C.sub.1-4 alkoxy, C.sub.1-6 alkynyl, halogen or amine,R.sub.3 =OH, hydrogen, C.sub.1-6 alkyl, C.sub.3-8 cycloalkyl, C.sub.1-4 alkoxy, Cl Br, I, CN, NH.sub.2, NHC.sub.1-6 alkyl, NC.sub.1-6 alkyl, OCOC.sub.1-6 alkyl, OCOC.sub.1-3 alkylaryl,A=S, 0 or NHX=H, C.sub.1-6 alkyl, C.sub.3-8 cycloalkyl, C.sub.1-4 alkoxy, C.sub.1-6 alkynyl, halogen, amino, acylamido, andZ=H, I, Br, Cl, F, CN, CF.sub.3 NO.sub.2, N.sub.3, OR.sub.1, CO.sub.2 NH.sub.2, CO.sub.2 R.sub.1, C.sub.1-6 alkyl , NR.sub.4 R.sub.5, NHCOR.sub.5, NHCO.sub.2 R.sub.6,wherein R.sub.4 -R.sub.6 are each C.sub.1-6 alkyl.
    Type: Grant
    Filed: April 26, 1994
    Date of Patent: January 10, 1995
    Assignees: Research Triangle Institute, The United States of America as represented by the Department of Health and Human Servies
    Inventors: Michael J. Kuhar, John W. Boja, Frank I. Carroll, Anita H. Lewin, Philip Abraham
  • Patent number: 5312734
    Abstract: The invention described in this disclosure relates to a cloned cDNA encoding the dopamine transporter protein usually found in certain neural cells. The invention is further directed to the purified dopamine transporter protein and its use as a biosensor material and immunogen for the production of anti-DAT1 antibodies. The disclosure also discusses methods for use of the cDNA for diagnostic and treatment applications, and methods for use of permanent cell lines transformed with the dopamine transporter cDNA for pharmaceutical screening. The use of anti-DAT1 antibodies as a diagnostic tool is also addressed.
    Type: Grant
    Filed: September 20, 1991
    Date of Patent: May 17, 1994
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: George R. Uhl, Michael J. Kuhar, Shoichi Shimada, Shigeo Kitayama, Amrat Patel, Chien-Liang Lin
  • Patent number: 5128118
    Abstract: 3.beta.-[4-iodophenyl]-tropan-2.beta.-carboxylic acid methyl ester tartrate is a high affinity binding ligand for neurotransmitters in mammalian brains. It and its congeners may be employed for imaging and other brain scanning techniques that allow the determination of the presence of cocaine receptors, such as neurotransmitters and the like.
    Type: Grant
    Filed: August 9, 1990
    Date of Patent: July 7, 1992
    Assignee: Research Triangle Institute
    Inventors: Frank I. Carroll, Anita H. Lewin, Philip Abraham, Michael J. Kuhar, John W. Boja